GHK-Cu (Copper Peptide): What the Evidence Actually Shows

GHK-Cu is one of the oldest and most-hyped “regenerative” peptides. You’ll see it sold for skin aging, hair, and wound healing. The lab science behind it is genuinely interesting. But the human evidence is thinner — and less independent — than the marketing makes it sound.

What it is

GHK-Cu is a tiny peptide (a short chain of amino acids) called glycyl-L-histidyl-L-lysine, attached to a single copper ion. Your body already makes it: it shows up naturally in blood plasma, saliva, and urine, and those levels drop as you get older. It grabs onto copper very tightly, and that copper-grabbing is thought to be the key to how it works. In cosmetics it goes by the ingredient name copper tripeptide-1 (the standardized label name used on product packaging). You’ll find it sold three main ways — as a topical serum or cream, as an injectable from compounding pharmacies (pharmacies that mix custom formulations), and as a research-grade powder.

The claims

Sellers and clinics say GHK-Cu does a lot: boosts collagen and elastin (the proteins that keep skin firm and springy), smooths wrinkles, tightens skin, speeds up wound healing, regrows hair, calms inflammation, and works as a broad “anti-aging” or even whole-body regenerative agent. Some go further and claim it “reprograms” cells at the level of their genes.

What the evidence actually shows

The lab and mechanism research is substantial. In studies on cells and animals, GHK-Cu revs up fibroblasts (the skin cells that build collagen), adjusts collagen and metalloproteinase activity (enzymes that break down tissue), and shifts the activity of thousands of genes. A widely cited review written by the peptide’s own discoverer reports that it can dial a large fraction of human genes up or down in cultured cells. These are real results — but they’re mostly in vitro (in a dish) and in rodents. And “changes gene activity in a dish” is not the same thing as helping a real person.

Human data exists, but it’s limited. The best of it comes from a handful of small, roughly 12-week, placebo-controlled facial cosmetic trials (each with maybe a few dozen women), which reported modest gains in firmness, density, fine lines, and clarity. There are also older reports on healing diabetic ulcers and post-surgery skin. Here’s the catch: much of the foundational human research and many of the reviews came from the peptide’s discoverer or from industry-linked groups, and there are no large, independent randomized trials (studies that randomly assign people to treatment or placebo to fairly compare them). There’s also a basic delivery question. GHK-Cu is a charged, water-loving molecule, and studies disagree on how much of it actually gets through unbroken skin. One in vitro penetration study found that meaningful amounts could pass through skin layers, while a 2025 review concluded that its skin penetration hasn’t been well measured yet — and that how it’s formulated (for example, packing it inside liposomes, tiny fatty bubbles that help carry ingredients) probably matters a lot. For injected or whole-body anti-aging use, real human outcome data is essentially nonexistent.

Legal and regulatory status

GHK-Cu is not an FDA-approved drug for any use. As a topical cosmetic ingredient it’s sold widely, but cosmetics legally can’t claim to treat disease. The compounding situation changed in 2026: the FDA removed non-injectable GHK-Cu from its Category 1 list and injectable GHK-Cu from its Category 2 “do not compound” list. Law firms that follow the FDA closely point out that both changes happened simply because the underlying requests were withdrawn — not because the FDA found it safe or effective — and that GHK-Cu is set for a Pharmacy Compounding Advisory Committee (PCAC) review before the end of February 2027. This is the important part: being taken off these lists is not the same as approval, and on its own it does not make GHK-Cu eligible for legal compounding. It is not a green light. WADA (the World Anti-Doping Agency) does not name GHK-Cu on its 2026 Prohibited List, but a substance with no regulatory approval can still get swept up by the “non-approved substances” catch-all rule, which bans such substances at all times — so athletes shouldn’t assume it’s allowed.

Safety

Topical GHK-Cu is generally well tolerated, with the occasional bit of irritation. Injected and whole-body safety in humans, on the other hand, is poorly understood — there are no large safety trials, how sterile and how dosed it is depends entirely on where it came from, and copper has a real toxic limit, so loading the body with it long-term is a genuine unknown. Avoid it during pregnancy and in copper-related conditions such as Wilson’s disease (an inherited disorder where copper builds up in the body). None of this is medical advice.

Bottom line

GHK-Cu has a strong mechanism story and some encouraging — but small, short, and industry-tied — topical trials. That makes it promising, not proven, and much weaker for injected use. Think of it as a cosmetic ingredient with early human support, not a validated therapy.

Evidence grade: 5/10 · Early.

Sources

• Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015.
• Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research, 2011.
• Ogórek K, et al. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules, 2025.
• Copper peptide GHK-Cu (overview and INCI name copper tripeptide-1).
• FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 / 503A interim policy).
• Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List (2026).
• Frier Levitt. FDA to Remove 12 Peptides from the Category 2 ‘Do Not Compound’ List (2026).
• WADA. The Prohibited List (2026).